Jun 13, 2022 / 12:00PM GMT
Operator
Good morning, ladies and gentlemen, and welcome to the Day One Biopharmaceuticals FIREFLY-1 Trial Initial Data Conference Call. At this time, all participants are in listen-only mode. Later, we will conduct a question and answer session. Please be advised that this conference call is being recorded.
(Operator Instructions) I would now like to turn the call over to Joey Perrone, Vice President of Finance and Investor Relations.
Joey Perrone - Day One Biopharmaceuticals - Vice President of Finance and Investor Relations
Thank you, [Olivia]. Good morning. And thank you for joining us today. Yesterday, we issued a press release providing an overview of the initial data from the ongoing pivotal Phase 2 FIREFLY-1 clinical trial with Tovorafenib in Relapsed Pediatric Low-Grade Glioma.
Slides to accompany this conference call are posted on the investors and media section of our website at www.a1biocom. And audio webcast with the corresponding slide is also available on the website.
Joining me on the call this morning are Dr. Jeremy Bender,
Day One Biopharmaceuticals Inc Initial Data from Pivotal FIREFLY-1 Trial of Tovorafenib Conference Call Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot